Corbett Grant T, Gonzalez Frank J, Pahan Kalipada
Graduate Program in Neuroscience, Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612;
Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892;
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8445-50. doi: 10.1073/pnas.1504890112. Epub 2015 Jun 15.
Amyloid precursor protein (APP) derivative β-amyloid (Aβ) plays an important role in the pathogenesis of Alzheimer's disease (AD). Sequential proteolysis of APP by β-secretase and γ-secretase generates Aβ. Conversely, the α-secretase "a disintegrin and metalloproteinase" 10 (ADAM10) cleaves APP within the eventual Aβ sequence and precludes Aβ generation. Therefore, up-regulation of ADAM10 represents a plausible therapeutic strategy to combat overproduction of neurotoxic Aβ. Peroxisome proliferator-activated receptor α (PPARα) is a transcription factor that regulates genes involved in fatty acid metabolism. Here, we determined that the Adam10 promoter harbors PPAR response elements; that knockdown of PPARα, but not PPARβ or PPARγ, decreases the expression of Adam10; and that lentiviral overexpression of PPARα restored ADAM10 expression in Ppara(-/-) neurons. Gemfibrozil, an agonist of PPARα, induced the recruitment of PPARα:retinoid x receptor α, but not PPARγ coactivator 1α (PGC1α), to the Adam10 promoter in wild-type mouse hippocampal neurons and shifted APP processing toward the α-secretase, as determined by augmented soluble APPα and decreased Aβ production. Accordingly, Ppara(-/-) mice displayed elevated SDS-stable, endogenous Aβ and Aβ1-42 relative to wild-type littermates, whereas 5XFAD mice null for PPARα (5X/α(-/-)) exhibited greater cerebral Aβ load relative to 5XFAD littermates. These results identify PPARα as an important factor regulating neuronal ADAM10 expression and, thus, α-secretase proteolysis of APP.
淀粉样前体蛋白(APP)衍生物β-淀粉样蛋白(Aβ)在阿尔茨海默病(AD)的发病机制中起重要作用。β-分泌酶和γ-分泌酶对APP进行顺序蛋白水解产生Aβ。相反,α-分泌酶“解整合素和金属蛋白酶”10(ADAM10)在最终的Aβ序列内切割APP,从而阻止Aβ的产生。因此,上调ADAM10是对抗神经毒性Aβ过量产生的一种可行治疗策略。过氧化物酶体增殖物激活受体α(PPARα)是一种调节参与脂肪酸代谢基因的转录因子。在此,我们确定Adam10启动子含有PPAR反应元件;敲低PPARα而非PPARβ或PPARγ会降低Adam10的表达;并且PPARα的慢病毒过表达可恢复Ppara(-/-)神经元中ADAM10的表达。吉非贝齐是一种PPARα激动剂,可诱导PPARα:视黄醇X受体α而非PPARγ共激活因子1α(PGC1α)募集至野生型小鼠海马神经元的Adam10启动子,并使APP加工向α-分泌酶方向转变,这可通过可溶性APPα增加和Aβ产生减少来确定。相应地,与野生型同窝小鼠相比,Ppara(-/-)小鼠的十二烷基硫酸钠稳定的内源性Aβ和Aβ1-42升高,而PPARα缺失的5XFAD小鼠(5X/α(-/-))相对于5XFAD同窝小鼠表现出更大的脑Aβ负荷。这些结果表明PPARα是调节神经元ADAM10表达从而调节APP的α-分泌酶蛋白水解的重要因子。